
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc. is positioned favorably within the biotech sector, focusing on therapies for serious diseases linked to immune system dysregulation, with its lead product candidates showing potential for addressing significant market needs. The current market valuation, while adjusted to $40 based on a net present value analysis, still reflects a substantial upside opportunity compared to the present share price, indicating potential for investor returns. Furthermore, the increasing incidence of idiopathic pulmonary fibrosis (IPF), with over 40,000 new cases diagnosed annually, underscores a growing demand for innovative treatments such as those being developed by GRI Bio.
Bears say
GRI Bio Inc. reported a net loss of $3.9 million, translating to an earnings per share (EPS) of $(7.72), which fell short of both internal estimates and consensus expectations, reflecting underlying financial weaknesses. The company is facing significant risks, including balance sheet and liquidity concerns, the potential failure of product candidates to prove safety and efficacy, and challenges in gaining regulatory approvals and commercialization. Additionally, external factors such as changing investor sentiment toward biotech stocks and macroeconomic fluctuations further contribute to a negative outlook for GRI Bio's stock.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares